Clinical Trial Update: A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis [Phase 1]

View source ↗

Summary

A Phase 1b proof-of-concept trial evaluating FE 999322 and FE 999324 in adults with mild to moderate ulcerative colitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• FE 999322
• FE 999324

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Ulcerative Colitis | Phase 1 | Status: WITHDRAWN